Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

Cell Reports

Volumn 8, Issue 4, 2014, Pages 1037-1048

  Sos, Martin L ^a   Levin, Rebecca S ^a,b   Gordan, John D ^a   Oses Prieto, Juan A ^b   Webber, James T ^a   Salt, Megan ^a   Hann, Byron ^a   Burlingame, Alma L ^b   McCormick, Frank ^a   Bandyopadhyay, Sourav ^a   Shokat, Kevan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 0048 48; A 0048 58; B RAF KINASE INHIBITOR; INTERLEUKIN 6; JANUS KINASE; K RAS PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RANTES; RAS PROTEIN; RO 5126766; SELUMETINIB; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BENZAMIDE DERIVATIVE; BRAF PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; DIPHENYLAMINE; IL6 PROTEIN, HUMAN; NICOTINAMIDE; SORAFENIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BODY WEIGHT; BRAF GENE; CANCER INHIBITION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESISTANCE; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENOMICS; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOLECULAR MIMICRY; MOLECULARLY TARGETED THERAPY; MOUSE; NIPA GENE; NONHUMAN; ONCOGENE K RAS; ONCOGENE MIMICRY; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MISSENSE MUTATION; NUDE MOUSE; ONCOGENE; SECRETION (PROCESS); TUMOR CELL LINE; CANCER CELL; CELL MUTANT; PHENOTYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOCRINE COMMUNICATION; BENZAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; DIPHENYLAMINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION, MISSENSE; NIACINAMIDE; ONCOGENES; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS B-RAF; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908356209     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.07.010     Document Type: Article

References (38)

1. Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., Hann B., Koch K.M., Shokat K.M., Moasser M.M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2010, 2:ra7.
2. Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21:1714-1719.
3. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004, 91:355-358.
4. Bankston D., Dumas J., Natero R., Riedl B., Monahan M.-K., Sibley R. A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer. Org. Process Res. Dev. 2001, 6:777-781.
5. Bassermann F., von Klitzing C., Münch S., Bai R.Y., Kawaguchi H., Morris S.W., Peschel C., Duyster J. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 2005, 122:45-57.
6. Bid H.K., Kibler A., Phelps D.A., Manap S., Xiao L., Lin J., Capper D., Oswald D., Geier B., DeWire M., et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an invivo model of childhood astrocytoma. Clin. Cancer Res. 2013, 19:6716-6729.
7. Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., et al. Discovery of pyrrolopyrimidine inhibitors of Akt. Bioorg. Med. Chem. Lett. 2010, 20:5607-5612.
8. Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., Shokat K.M., Barford D. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011, 472:366-369.
9. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
10. Clauser K.R., Baker P., Burlingame A.L. Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal. Chem. 1999, 71:2871-2882.
11. Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Della Pelle P., Dias-Santagata D., Hung K.E., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
12. Cooper M.J., Cox N.J., Zimmerman E.I., Dewar B.J., Duncan J.S., Whittle M.C., Nguyen T.A., Jones L.S., Ghose Roy S., Smalley D.M., et al. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLoS One 2013, 8:e66755.
13. Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Körner R., Greff Z., Kéri G., Stemmann O., Mann M. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 2008, 31:438-448.
14. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
15. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
16. Falchook G.S., Lewis K.D., Infante J.R., Gordon M.S., Vogelzang N.J., DeMarini D.J., Sun P., Moy C., Szabo S.A., Roadcap L.T., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13:782-789.
17. Graves L.M., Duncan J.S., Whittle M.C., Johnson G.L. The dynamic nature of the kinome. Biochem. J. 2013, 450:1-8.
18. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
19. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
20. Illert A.L., Zech M., Moll C., Albers C., Kreutmair S., Peschel C., Bassermann F., Duyster J. Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M. J.Biol. Chem. 2012, 287:37997-38005.
21. Jänne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., Franke F.A., Grinsted L., Zazulina V., Smith P., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14:38-47.
22. Kudchadkar R., Paraiso K.H., Smalley K.S. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 2012, 18:124-131.
23. Lito P., Pratilas C.A., Joseph E.W., Tadi M., Halilovic E., Zubrowski M., Huang A., Wong W.L., Callahan M.K., Merghoub T., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
24. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
25. Nan X., Collisson E.A., Lewis S., Huang J., Tamgüney T.M., Liphardt J.T., McCormick F., Gray J.W., Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc. Natl. Acad. Sci. USA 2013, 110:18519-18524.
26. Ouyang T., Bai R.Y., Bassermann F., von Klitzing C., Klumpen S., Miething C., Morris S.W., Peschel C., Duyster J. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J.Biol. Chem. 2003, 278:30028-30036.
27. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
28. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
29. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
30. Rushworth L.K., Hindley A.D., O'Neill E., Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
31. Schilling B., Rardin M.J., MacLean B.X., Zawadzka A.M., Frewen B.E., Cusack M.P., Sorensen D.J., Bereman M.S., Jing E., Wu C.C., et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol. Cell. Proteomics 2012, 11:202-214.
32. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. 1995, 9:726-735.
33. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
34. Sos M.L., Fischer S., Ullrich R., Peifer M., Heuckmann J.M., Koker M., Heynck S., Stückrath I., Weiss J., Fischer F., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. USA 2009, 106:18351-18356.
35. Statsuk A.V., Maly D.J., Seeliger M.A., Fabian M.A., Biggs W.H., Lockhart D.J., Zarrinkar P.P., Kuriyan J., Shokat K.M. Tuning a three-component reaction for trapping kinase substrate complexes. J.Am. Chem. Soc. 2008, 130:17568-17574.
36. Tanaka M., Bateman R., Rauh D., Vaisberg E., Ramachandani S., Zhang C., Hansen K.C., Burlingame A.L., Trautman J.K., Shokat K.M., Adams C.L. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005, 3:e128.
37. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
38. Zhu Z., Aref A.R., Cohoon T.J., Barbie T.U., Imamura Y., Yang S., Moody S.E., Shen R.R., Schinzel A.C., Thai T.C., et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014, 4:452-465.